Image

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called " gene panel ". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called "high-throughput exome sequencing (SHD-E)", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.

Description

The main objective of this study is to evaluate the interest of the SHD-E approaches after a negative result of the analysis called " gene panel " tested in routine in order to identify a genetic factor of predisposition to the cancer.

Eligibility

Inclusion Criteria:

Index case:

  1. Major or minor patient
  2. Histological or cytological evidence of malignant tumor diagnosis
  3. Patient with cancer before age 40 (or before age 30 for breast cancer).
  4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned
  5. Patient affiliated to a social security scheme
  6. Signature of Informed Consent EXTRICAN
  7. Availability of a tumor sample if needed secondary functional studies
  8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)
  9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)
    Related
  10. Major or minor patient
  11. Histological or cytological evidence of the diagnosis of malignant tumor if
  12. Patient affiliated to a social security scheme
  13. Signing informed consent EXTRICAN

Exclusion Criteria:

Index and related case:

  1. Refusal of the patient participation
  2. Psychiatric illness and / or condition of the patient compromising the understanding of the information or the realization of the study
  3. Patient under guardianship, curatorship or safeguard of justice
  4. Pregnant woman

Study details
    Cancer
    Genetic Predisposition

NCT04141462

Centre Georges Francois Leclerc

21 February 2024

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.